Strache R R, Büttner H H, Göcze P M, Briese V
Frauenklinik des Bezirkskrankenhauses, Wismar, Bundesrepublik Deutschland.
Zentralbl Gynakol. 1990;112(23):1445-53.
It should be solved the question if the estimation of the TSA-concentrations in various body fluids of patients with ovarian tumour like conditions (n = 11), and benign (n = 28) and malignant (n = 25) cystic ovarian tumours can be used as a tumour marker with an additional clinical information. The determination of the concentrations were carried out in blood sera, cyst and peritoneal fluids. The periodate-thiobarbituric acid-assay was used to measure the TSA-contents. The sensitivity of pre-therapy TSA-concentrations in serum for malignant cystic ovarian tumours is 0.59 at a prevalence of 0.55; the specificity has a value of 0.79. There is no improvement of clinical validity through a pre-therapy TSA/total protein (TP)-ratio in serum (sensitivity 0.41; specificity 0.71). There are no useful clinical data of simultaneous estimation in serum, tumour cystic and peritoneal fluids of the same patient.
对于患有卵巢肿瘤样疾病的患者（n = 11）以及良性（n = 28）和恶性（n = 25）卵巢囊性肿瘤患者，其各种体液中TSA浓度的估计是否可作为一种具有额外临床信息的肿瘤标志物，这一问题有待解决。浓度测定在血清、囊肿和腹腔液中进行。采用高碘酸盐 - 硫代巴比妥酸测定法测量TSA含量。血清中治疗前TSA浓度对恶性卵巢囊性肿瘤的敏感性在患病率为0.55时为0.59；特异性值为0.79。血清中治疗前TSA/总蛋白（TP）比值并未提高临床有效性（敏感性0.41；特异性0.71）。对于同一患者的血清、肿瘤囊肿和腹腔液同时进行估计，没有有用的临床数据。
